Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.

ABSTRACT: The advent of molecularly targeted agents for patients with peripheral T-cell lymphomas (PTCL) has begun to change the therapeutic landscape in these diseases, especially for patients with relapsed or refractory disease. These agents, grounded in targeting numerous pathways or alterations related to disease pathogenesis, have shown promise across many PTCL subhistologies. Aided by significant advances in experimental techniques related to molecular biology, epigenetics, and immunology, more recent studies have begun elucidating mediators of resistance, both intrinsic and acquired, to inform future therapeutic advances. Defining and targeting these escape mechanisms through rational combination approaches will likely be important to continue to build on these promising advances and further

SUBMITTER: Epstein-Peterson ZD 

PROVIDER: S-EPMC8496899 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature